Liberty Analyzer WBC System: Reference Interval Study (REFINE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Hannah Rawlinson-Smith
- Phone Number: +447599481041
- Email: hannah.rawlinson-smith@entia.co
Study Contact Backup
- Name: Entia Clinical Team
- Phone Number: +447599481041
- Email: clinical@entia.co
Study Locations
-
-
Texas
-
College Station, Texas, United States, 77843
- Exercise & Sport Nutrition Laboratory
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged ≥21 years old at the time of study entry
- Able to provide written informed consent
Exclusion Criteria:
- Inadequate use and understanding of the English language, requiring a translator
- Undergone tattooing or body piercing within the 7 days prior to the study visit
- Undergone vaccination within the 7 days prior to the study visit
- Episode of upper respiratory infection within the 30 days prior to the study visit
- Use of oral corticosteroid medications within the 30 days prior to the study visit
- Undergone surgery within the 90 days prior to the study visit
- Been hospitalised within the 90 days prior to the study visit
- Donated blood or plasma within the 90 days prior to the study visit
- Pregnant at the time of the study visit
- Breastfeeding at the time of the study visit
- Current diagnosis of anemia (including iron deficiency anemia, vitamin deficiency anemia, aplastic anemia and/or hemolytic anemia)
- Current diagnosis of high blood pressure
- Current diagnosis of diabetes mellitus
- History or current diagnosis of chronic kidney disease or end-stage renal disease
- History or current diagnosis of cancer
- History or current diagnosis of cardiovascular disease
- History or current use of radiotherapy of the chest or abdomen
- History or current diagnosis of the following conditions known to affect the CBC differential count:
- Immune Thrombocytopenic Purpura (ITP)
- Systemic Lupus Erythematosus (SLE)
- Rheumatoid Arthritis (RA)
- Antiphospholipid Syndrome (APS)
- Sjogren's Syndrome
- Tuberculosis (TB)
- HIV
- Hepatitis B/C
- G6PD Deficiency
- Sickle Cell Disease/Trait
- Inflammatory Bowel Disease (IBD)
- Eptein Barr virus
- CMV Cytomegalovirus
- Myelodysplastic Syndromes (MDS) / CMML
- Asplenia
Participants who meet the following criteria will be excluded a posteriori:
- Hemoglobin, hematocrit, red cell and/or total white blood cell count obtained by standard laboratory analysis of the participant's venous blood sample, that fall(s) outside of the applicable reference interval(s) in use at the study site.
- Iron, ferritin, transferrin, total Iron Binding Capacity (TIBC) and/or transferrin saturation results obtained by standard laboratory analysis of the participant's venous blood sample, that fall(s) outside of the applicable reference interval(s) in use at the study site.
- Alanine aminotransferase (ALT), aspartate aminotransferase ( AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin, conjugated bilirubin, albumin and/or total protein results obtained by standard laboratory analysis of the participant's venous blood sample, that fall(s) outside of the applicable reference interval(s) in use at the study site.
- Creatinine, estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN), sodium, potassium, chloride and/or bicarbonate results obtained by standard laboratory analysis of the participant's venous blood sample, that fall(s) outside of the applicable reference interval(s) in use at the study site.
- C-reactive protein (CRP) results obtained by standard laboratory analysis of the participant's venous blood sample, that fall outside of the applicable reference interval in use at the study site.
- Self-report to be taking medication(s) that are subsequently identified as interfering substances for the Liberty Analyzer WBC System
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Healthy volunteers
|
Participants will donate capillary samples to be analysed by the Liberty Analyzer System WBC
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To establish the 95% reference interval for WBC for the Liberty Analyzer WBC System, reported with 90% confidence intervals.
Time Frame: Through study completion, an average of 1 day
|
Through study completion, an average of 1 day
|
|
To establish the 95% reference interval for absolute granulocytes for the Liberty Analyzer WBC System, reported with 90% confidence intervals.
Time Frame: Through study completion, an average of 1 day
|
Through study completion, an average of 1 day
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CTM-PRO-00174
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.